Renan Ozyerli, MD, MSD Turkey
Renan Ozyerli of MSD Turkey provides insights into the transformation of Turkey’s healthcare ecosystem over the past decade, highlighting how MSD works hand-in-hand with the government to broaden access to…
MSD entered the Turkish pharma market in 1989 and established a subsidiary in 1993.
The headquarters are based in Istanbul. MSD employs 463 people in Human Health, as well as 32 people in Animal Health. Products are sourced from the global MSD network and toll manufacturing from 4 local companies. The subsidiary has a fully operational warehouse.
Currently, MSD Turkey is participating in 23 international clinical trials at 113 study centers. As such, the affiliate ranks among the top 3 research-based pharma companies in terms of clinical research capability. MSD Turkey also houses the management oversight/responsibility of Middle East and Egypt with 6 trials and 21 study centers in 5 different countries. In 2014, Merck HQ funded TRY 20.7 million (USD 9.5 million) to Turkey for clinical trials.
Contact Details
Merck Sharp Dohme İlaçları Ltd. Şti.
Esentepe Mah. Büyükdere Cad. No: 199
Levent 199 Ofis Bloğu Kat: 13, 34394 Levent-İstanbul
Tel:+90 212 336 1000
Fax:+90 212 215 2733
http://www.msd.com.tr/
Renan Ozyerli of MSD Turkey provides insights into the transformation of Turkey’s healthcare ecosystem over the past decade, highlighting how MSD works hand-in-hand with the government to broaden access to…
MSD Turkey has benefited in recent years from the ability to engage in local business development initiatives, and managing director Hatice Demiray has prioritized initiatives such as reducing internal bureaucracy…
A roundup of the latest pharma and healthcare news from Turkey including Omya’s new Turkish manufacturing site, Santa Farma’s fourth EU-GMP certification and the collaboration agreement between BioNTech and Turkey’s…
A roundup of the latest pharma and healthcare news from Turkey including Roche Turkey’s digital platform for HCPs and patients, big pharma’s aid to earthquake victims, the Scientific and Technological…
The Middle East and Africa (MEA), the fifth-largest regional pharma market in the world, is rapidly becoming a pharmaceutical powerhouse with both global and local firms taking advantage of the…
After its best financial year to date – posting revenues of USD 27.3 billion in 2021 – Gilead has said yes to localization in Turkey. The California-based company, known for…
Turkey’s pharma market, the 18th largest in the world and valued at USD 7 Billion in 2020, has seen steady growth over the past few years due to favorable healthcare…
With an already well-established manufacturing industry for pharmaceuticals, Turkey has been aiming to move with global trends and invest in biologics production, specifically in biosimilars. The share of biotechnological…
Becoming the clinical trials country leader in the region has been set as a primary goal for Turkey’s pharma industry to achieve global competitiveness. The government’s strategy is to increase…
Few Turkish companies are experiencing such a transformational moment as GEN. In 2021 alone, the Ankara-based organization made its public debut on the Istanbul Stock Exchange and signed an exclusive…
When the Turkish Ministry of Health implemented its strategy to transition from import pharmaceuticals to manufacturing them at home in 2016, the local industry leveraged the situation to invest in…
As an upper-middle-income country with an emerging economy, Turkey could not invest billions in COVID-19 vaccine R&D, but a strong research ecosystem and willing industry allowed it to kickstart multiple…
Overseeing healthcare for a population of over 80 million, Turkey’s Ministry of Health was put under the spotlight during the COVID-19 pandemic. Here, we highlight four of the hot-button items…
There are perhaps no two words that better summarize the last few years in Turkish pharma than localization and pricing. But after years of investment and struggles, the country’s priorities…
See our Cookie Privacy Policy Here